Showing results (91-100 of 108) with videos related to
Sort By:
Pageof 11
European Journal of Cancer (Oxford, England : 1990)|April 26, 2023
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma IntergroupMarco Rubatto, Paolo Fava, Ignazio Stanganelli, et al.Journal of Translational Medicine|December 17, 2025
High BRAF variant allele frequency predicts poor outcomes in metastatic melanoma patients treated with BRAF/MEK inhibitorsMichele Guida, Benedetta Apollonio, Luca Romano, et al.Plos One|August 30, 2014
Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis surveyDaniele Santini, Francesco Pantano, Ferdinando Riccardi, et al.NEJM Evidence|September 24, 2024
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in MelanomaPaolo A Ascierto, Mario Mandalà, Pier Francesco Ferrucci, et al.Nature Communications|January 3, 2024
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trialPaolo A Ascierto, Milena Casula, Jenny Bulgarelli, et al.Journal for Immunotherapy of Cancer|November 30, 2022
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registriesAlessio Cortellini, Gino M Dettorre, Urania Dafni, et al.Therapeutic Advances in Medical Oncology|January 22, 2024
Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registryBruno Vincenzi, Alessio Cortellini, Alessandro Mazzocca, et al.Journal for Immunotherapy of Cancer|November 6, 2020
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practiceAlessio Cortellini, Marco Tucci, Vincenzo Adamo, et al.European Journal of Cancer (Oxford, England : 1990)|February 10, 2024
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studiesAlessandro Parisi, Blandine Delaunay, Giada Pinterpe, et al.Journal for Immunotherapy of Cancer|May 4, 2026
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastasesMario Mandalà, Monica F Chen, Ryan J Sullivan, et al.Pageof 11